Dulaglutide
Trulicity is a prescription GLP-1 product with indication-specific diabetes context.
FDA-approved product context
Trulicity is a prescription GLP-1 product with indication-specific diabetes context.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Evidence and source limits
The Trulicity label identifies dulaglutide as a GLP-1 receptor agonist for subcutaneous use; it includes evidence for glycemic control in type 2 diabetes, including patients age 10 and older. This note follows the retrieved August 2023 label, not a claim that every product has identical current labeling.
Its boxed warning concerns thyroid C-cell tumors. Other warnings include pancreatitis, hypoglycemia with some diabetes medicines, kidney injury, severe gastrointestinal disease and hypersensitivity.
Approval applies to the specific labeled product, route and indication, not every preparation of this ingredient or a wellness mixture. Read the original full label and discuss individual circumstances with a medical professional. No dosing or preparation instructions are included.
Original source: Dulaglutide ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.